FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
ReShape Lifesciences Inc. [ RSLS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 03/25/2020 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Series G Warrants | (2) | 03/25/2020 | J(2) | 1,200,000 | 03/25/2020 | 03/25/2025 | COMMON STOCK | 1,200,000 | (2) | 1,200,000 | D(1) | ||||
Series G Warrants | (2) | 03/25/2020 | J(2) | 0 | 03/25/2020 | 03/25/2025 | COMMON STOCK | 0 | (2) | 1,200,000 | I | See Footnote(1) | |||
Series F Prefunded Warrants | (3) | 09/23/2019 | (4) | COMMON STOCK | 2,569,167 | 2,569,167 | D(1) | ||||||||
Series F Prefunded Warrants | (3) | 09/23/2019 | (4) | COMMON STOCK | 0 | 2,569,167 | I | See Footnote(1) | |||||||
Series E Warrants | (5) | 09/23/2019 | 11/12/2020 | COMMON STOCK | 2,625,000 | 2,625,000 | D(1) | ||||||||
Series E Warrants | (5) | 09/23/2019 | 11/12/2020 | COMMON STOCK | 0 | 2,625,000 | I | See Footnote(1) | |||||||
Series A Warrants | (6) | 06/18/2019 | 11/12/2024 | COMMON STOCK | 2,625,000 | 2,625,000 | D(1) | ||||||||
Series A Warrants | (6) | 06/18/2019 | 11/12/2024 | COMMON STOCK | 0 | 2,625,000 | I | See Footnote(1) | |||||||
Series C Prefunded Warrants | (7) | 06/18/2019 | (8) | COMMON STOCK | 2,516,667 | 2,516,667 | D(1) | ||||||||
Series C Prefunded Warrants | (7) | 06/18/2019 | (8) | COMMON STOCK | 0 | 2,516,667 | I | See Footnote(1) |
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
Explanation of Responses: |
1. The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation (the "Master Fund"), and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital") as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
2. The Issuer issued to the Master Fund series G warrants of the Issuer (collectively, the "Series G Warrants") in connection with a credit agreement entered into between the Issuer and the Master Fund on March 25, 2020. The exercise price of each Series G Warrant is the lesser of: (i) $3.70; or (ii) the average of the two lowest volume weighted average prices for the Shares during the 10 trading days immediately prior to the exercise date, subject to adjustment pursuant to the terms of the Series G Common Stock Purchase Warrant. |
3. The exercise price of each Series F Prefunded Warrant is $0.001 per Share, subject to adjustment pursuant to the terms of the Series F Prefunded Warrants. |
4. The Series F Prefunded Warrants have a perpetual term. |
5. The exercise price of each Series E Warrant is $0.05, subject to adjustment pursuant to the terms of the Series E Warrants. |
6. The exercise price for each Series A Warrant is $0.022 per share of Common Stock, subject to adjustment pursuant to the terms of the Series A Warrants. |
7. The exercise price for each Series C Prefunded Warrant is $0.001 per share of Common Stock, subject to adjustment pursuant to the terms of the Series C Prefunded Warrants. |
8. The Series C Prefunded Warrants have a perpetual term. |
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member | 03/27/2020 | |
Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd, Director | 03/27/2020 | |
/s/ Steven Boyd | 03/27/2020 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |